At the 62nd Annual Meeting of the ACC, scholars from Japan presented the results of the one-year NEXT trial of biodegradable stents and drug-eluting stents. The drug-eluting stent was placed into the stenotic coronary vessel to restore blood flow, and the stent was coated with a polymer to prevent restenosis and revascularization. The polymer drug significantly reduced restenosis and target lesion reconstruction rates, but the polymer itself delayed healing in the stented artery, triggering an inflammatory response that led to late adverse outcomes. The clinical challenge is to maintain the beneficial effects of the drug while eliminating or reducing its adverse effects. The polymer of the stent degrades 6 to 9 months after stent placement, and biolimus-eluting stents (BES) may reduce stenosis and very late stent thrombosis. The NEXT trial was a multicenter, randomized, open trial that enrolled 3,235 patients with either a BES or an everolimus stent (EES). 2011 saw the approval of the BES in Japan. While EES usage remains the first. The two eluting compounds belong to the same class of drugs. This study included 98 centers in Japan that needed to include patients requiring placement of drug-eluting stents. The incidence of target lesion reconstruction at 1 year was comparable between the BES and EES groups, both at 4.2% (67 patients in the BES group versus 66 patients in the EES group), with a defined stent thrombosis rate of 0.25% in the BES group versus 0.06 in the BES group. subgroup analysis in 528 patients showed that coronary angiography showed a similar incidence of restenosis in both groups, using a postoperative rate of 266± The other primary endpoints of this study were death after stent placement, and heart attack. Many of the patients in this study were elderly (mean age 69.2+9.8 years), had comorbid diabetes (46%) or had previous stent placement (51%). No differences were found between the two stent groups. The success rate of the acute procedure was high in both groups, reaching 99.6%.